Medexon SRL
Medexon reported total assets of 427,025 € at the end of the 2025 financial year (annual accounts filed with the NBB on 20 May 2026).
The score of Medexon shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +378 % Total assets +98 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Medexon's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −29,670 € | ||||
| Equity | 259,899 € | ||||
| Cash | 127,311 € | ||||
| EBITDA | 37,538 € | ||||
| Total assets | 427,025 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 May 2026
- Year ended 31 Dec 2024filed on 27 Aug 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 07 Jul 2022
Medexon's financial analysis
- Solvency60.9%sector median: 55.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Medexon
Medexon's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0743.962.284
- VAT number
- BE0743962284
- Peppol
- Registered · 0208:0743962284 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 Feb 2020
- Registered office
- 8400 Ostend
- Latest accounts
- 2025 · filed on 20 May 2026
- Activity
- Other business support service activities n.e.c. (NACE 82990)
Medexon (SRL) has been based in Ostend since 2020, active in: other business support service activities n.e.c.. For 2025, it reports a net loss of 29,670 € and equity of 259,899 €; its revenue is not published. Its solvency stands at 60.9%, above the median of its sector (55.4%).
Companies similar to Medexon
Companies in the same business, of comparable size and area, outside its group.
- Heart Link Online Other business support service activities n.e.c. Roosdaal · balance sheet 428,190 €
- Karul Other business support service activities n.e.c. Ghent · balance sheet 426,936 €
- FLEX Other business support service activities n.e.c. Dendermonde · balance sheet 427,361 €
- DR Ghisdal Nephrologie Other business support service activities n.e.c. Rixensart · balance sheet 427,596 €
- Write Management Other business support service activities n.e.c. Zemst · balance sheet 428,090 €
- Libran Other business support service activities n.e.c. Nazareth-De Pinte · balance sheet 425,548 €
- Thopen Other business support service activities n.e.c. Zele · balance sheet 425,008 €
- Van der Made Consulting Other business support service activities n.e.c. Ixelles · balance sheet 429,110 €
Frequently asked questions about Medexon
What is the revenue of Medexon?
Medexon files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Medexon?
In Belgium, the VAT number is the company number prefixed with BE: BE0743962284 for Medexon, if the company is VAT-registered. Its company number (CBE) is 0743.962.284.
Where is the registered office of Medexon?
According to the CBE register, the registered office of Medexon is in 8400 Ostend.
What is the equity of Medexon?
At the close of the 2025 financial year, the equity of Medexon amounts to 259,899 €, a solvency of 60.9% of total assets.
Who manages Medexon?
The register lists 3 active mandates at Medexon. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Medexon
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →